Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rxo (RXO) EBT (2021 - 2025)

Rxo's EBT history spans 5 years, with the latest figure at -$51.0 million for Q4 2025.

  • For Q4 2025, EBT fell 54.55% year-over-year to -$51.0 million; the TTM value through Dec 2025 reached -$115.0 million, up 62.17%, while the annual FY2025 figure was -$115.0 million, 62.17% up from the prior year.
  • EBT reached -$51.0 million in Q4 2025 per RXO's latest filing, down from -$15.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $59.0 million in Q2 2022 to a low of -$242.0 million in Q3 2024.
  • Average EBT over 5 years is -$11.3 million, with a median of -$4.5 million recorded in 2022.
  • Peak YoY movement for EBT: soared 166.67% in 2023, then tumbled 7966.67% in 2024.
  • A 5-year view of EBT shows it stood at $55.0 million in 2021, then plummeted by 110.91% to -$6.0 million in 2022, then skyrocketed by 166.67% to $4.0 million in 2023, then tumbled by 925.0% to -$33.0 million in 2024, then plummeted by 54.55% to -$51.0 million in 2025.
  • Per Business Quant, the three most recent readings for RXO's EBT are -$51.0 million (Q4 2025), -$15.0 million (Q3 2025), and -$10.0 million (Q2 2025).